Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1B, Single Center, Randomized, Open Label, Parallel Group Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single NGM313 Dose or Daily Oral Pioglitazone in Obese Participants With Insulin Resistance and Increased Liver Fat

Next Previous
X
Search
Trial Profile

A Phase 1B, Single Center, Randomized, Open Label, Parallel Group Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single NGM313 Dose or Daily Oral Pioglitazone in Obese Participants With Insulin Resistance and Increased Liver Fat

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 18 Jul 2019

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MK 3655 (Primary) ; Pioglitazone
  • Indications Obesity
  • Focus Pharmacodynamics; Proof of concept
  • Sponsors NGM Biopharmaceuticals

    • Most Recent Events

    • 11 Jun 2019 Results assessing effects of a single dose of NGM313 vs. daily pioglitazone (PIO) on insulin sensitivity, liver fat content (LFC) and lipids in insulin resistant, obese subjects with increased liver fat, presented at the 79th Annual Scientific Sessions of the American Diabetes Association.
    • 05 Jun 2019 According to a NGM Biopharmaceuticals media release, data were presented at the European Association for the Study of the Livers (EASL) The International Liver Congress (ILC) in April 2019.
    • 05 Jun 2019 According to a NGM Biopharmaceuticals media release, data ( evaluation of whole-body insulin sensitivity of a single dose of NGM313 compared to daily dosing of pioglitazone (45 mg) ) will be presented at the 79th Scientific Sessions of the American Diabetes Association (ADA).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top